Group 1 - Titan Technology's stock price has declined for eight consecutive days, with a total drop of 19.16%, currently trading at 24.38 CNY per share and a market capitalization of 4.009 billion CNY [1] - The company, established in October 2007 and listed in October 2020, provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, and specialized chemicals [1] - The revenue composition of Titan Technology includes 25.08% from proprietary specialty chemicals, 20.48% from proprietary high-end reagents, and 15.65% from third-party research instruments and consumables [1] Group 2 - Rongtong Fund holds 1.161 million shares of Titan Technology in its Rongtong Healthcare Industry Mixed Fund A/B, representing 3.28% of the fund's net value, making it the ninth largest holding [2] - During the eight-day decline, the fund has incurred a floating loss of approximately 670.98 thousand CNY [2] - The Rongtong Healthcare Industry Mixed Fund A/B has achieved a year-to-date return of 22.05% and a one-year return of 33.89% [2] Group 3 - The fund managers of Rongtong Healthcare Industry Mixed Fund A/B are Wan Minyuan and Liu Xiyang, with Wan having a tenure of nearly 10 years and a best fund return of 157.54% during his management [3] - Liu Xiyang has been managing the fund for about 1.5 years, with a best fund return of 4.17% during his tenure [3]